Abstract submission closed on Monday, April 6.
EAC will showcase abstract presentations from allergists, immunologists, and fellows-in-training. We invite you to participate by submitting your clinical research for review by our Abstract Committee. When preparing your abstract, please organize it into a statement of purpose, methods, and a summary of results, with sufficient detail to support your conclusions.
All abstracts will have the option to be published in Allergy & Asthma Proceedings
Poster Instructions
- Poster display size: 4 feet high by 6 feet wide.
- Illustrations and tables will not be printed in the program guide but may be included on the poster.
- Author affiliations may be included on the poster.
- Poster printing is the responsibility of the submitting author and/or presenter.
- Each poster will be displayed for one day only (Friday or Saturday).
- Assigned presentation days will be communicated by April 24.
- Mounting supplies (push pins) will be provided onsite.
- The poster presenter does not need to be the author, however the presenter must register for EAC.
Abstract Instructions
- A structured abstract format is required:
o Title
o Authors
o Introduction (background and purpose of the project/study)
o Methods (study design, techniques)
o Results (summary of data)
o Conclusions
o Funding, if appropriate
- The abstract title should fully reflect the content of the abstract body.
- The abstract must adequately describe the objectives, methods, results, and conclusions to allow the Abstract Committee to evaluate the quality of the work and the proposed presentation.
- Authors should be listed by first name, last name, and highest degree (e.g., John Smith, MD). Affiliations should not be included, as they will not be printed in the program guide however, they may be included in the final poster presentation.
- Supplementary data is not accepted under any circumstances.
- Abbreviations may be used in the abstract, provided they are defined at first mention.
- Abstract length is limited to 300 words.
- Abstracts must be submitted in a word.DOC format.
- Use font New Times Roman, size 12
- Only use bold for title and headings
- Encore abstracts are permitted.
- Wherever possible, non-commercial (generic) names should be used in all abstracts and posters. To ensure compliance with this ACCME requirement, the Abstract Committee may request a revised submission.
- All authors must disclose any non–FDA-approved use of FDA-approved drugs in the submission email only. No further disclosure is required.
- Authors must accept sole responsibility for the statements made in their submitted abstract.